drugset / Trial / NCT02033876

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

NCT02033876

Phase 2 Completed 24 enrolled Mayo Clinic
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance glycemic control. These observations will provide the preliminary data for proposing future therapeutic as well as further mechanistic studies of the role of bile acids in the control of glycemia in T2DM.

Timeline

Start
2013-10
Primary completion
2017-01
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 600 mg